2fjp
From Proteopedia
(New page: 200px<br /> <applet load="2fjp" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fjp, resolution 2.40Å" /> '''Human dipeptidyl pe...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:2fjp.gif|left|200px]]<br /> | + | [[Image:2fjp.gif|left|200px]]<br /><applet load="2fjp" size="350" color="white" frame="true" align="right" spinBox="true" |
| - | <applet load="2fjp" size=" | + | |
caption="2fjp, resolution 2.40Å" /> | caption="2fjp, resolution 2.40Å" /> | ||
'''Human dipeptidyl peptidase IV/CD26 in complex with an inhibitor'''<br /> | '''Human dipeptidyl peptidase IV/CD26 in complex with an inhibitor'''<br /> | ||
==Overview== | ==Overview== | ||
| - | A series of beta-substituted biarylphenylalanine amides were synthesized | + | A series of beta-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1 ,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models. Compound 6 was selected for further characterization as a potential new treatment for type 2 diabetes. |
==About this Structure== | ==About this Structure== | ||
| - | 2FJP is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with NAG and S14 as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Dipeptidyl-peptidase_IV Dipeptidyl-peptidase IV], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.14.5 3.4.14.5] Full crystallographic information is available from [http:// | + | 2FJP is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=NAG:'>NAG</scene> and <scene name='pdbligand=S14:'>S14</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Dipeptidyl-peptidase_IV Dipeptidyl-peptidase IV], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.14.5 3.4.14.5] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FJP OCA]. |
==Reference== | ==Reference== | ||
| Line 15: | Line 14: | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
| - | [[Category: Becker, J | + | [[Category: Becker, J W.]] |
| - | [[Category: Patel, S | + | [[Category: Patel, S B.]] |
[[Category: Scapin, G.]] | [[Category: Scapin, G.]] | ||
[[Category: NAG]] | [[Category: NAG]] | ||
| Line 24: | Line 23: | ||
[[Category: dimer]] | [[Category: dimer]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:22:05 2008'' |
Revision as of 15:22, 21 February 2008
|
Human dipeptidyl peptidase IV/CD26 in complex with an inhibitor
Overview
A series of beta-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1 ,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models. Compound 6 was selected for further characterization as a potential new treatment for type 2 diabetes.
About this Structure
2FJP is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Dipeptidyl-peptidase IV, with EC number 3.4.14.5 Full crystallographic information is available from OCA.
Reference
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1 ,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes., Edmondson SD, Mastracchio A, Mathvink RJ, He J, Harper B, Park YJ, Beconi M, Di Salvo J, Eiermann GJ, He H, Leiting B, Leone JF, Levorse DA, Lyons K, Patel RA, Patel SB, Petrov A, Scapin G, Shang J, Roy RS, Smith A, Wu JK, Xu S, Zhu B, Thornberry NA, Weber AE, J Med Chem. 2006 Jun 15;49(12):3614-27. PMID:16759103
Page seeded by OCA on Thu Feb 21 17:22:05 2008
Categories: Dipeptidyl-peptidase IV | Homo sapiens | Single protein | Becker, J W. | Patel, S B. | Scapin, G. | NAG | S14 | Alpha/beta | Beta-propeller | Dimer
